CA Patent

CA2223531A1 — Reducing gelation of a fatty acid-acylated protein

Assigned to Eli Lilly and Co · Expires 1996-12-19 · 29y expired

What this patent protects

A method for processing a fatty acid-acylated protein, especially N-palmitoyl LysB29 human insulin, to reduce the incidence of gelation by conducting such processing in the presence of a citrate buffering agent as the primary buffer which method allows such processing to be condu…

USPTO Abstract

A method for processing a fatty acid-acylated protein, especially N-palmitoyl LysB29 human insulin, to reduce the incidence of gelation by conducting such processing in the presence of a citrate buffering agent as the primary buffer which method allows such processing to be conducted at higher protein concentrations and with less temperature control than would otherwise be possible in the absence of the citrate buffer.

Drugs covered by this patent

Patent Metadata

Patent number
CA2223531A1
Jurisdiction
CA
Classification
—
Expires
1996-12-19
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.